CA2764499A1 - Interlaced method for treating cancer or a precancerous condition - Google Patents
Interlaced method for treating cancer or a precancerous condition Download PDFInfo
- Publication number
- CA2764499A1 CA2764499A1 CA2764499A CA2764499A CA2764499A1 CA 2764499 A1 CA2764499 A1 CA 2764499A1 CA 2764499 A CA2764499 A CA 2764499A CA 2764499 A CA2764499 A CA 2764499A CA 2764499 A1 CA2764499 A1 CA 2764499A1
- Authority
- CA
- Canada
- Prior art keywords
- dosage
- tumor
- cell cycle
- phase
- cancerous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 206010028980 Neoplasm Diseases 0.000 title claims description 46
- 201000011510 cancer Diseases 0.000 title claims description 15
- 208000006994 Precancerous Conditions Diseases 0.000 title claims description 7
- 230000022131 cell cycle Effects 0.000 claims abstract description 35
- 230000018199 S phase Effects 0.000 claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 18
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 16
- 230000005855 radiation Effects 0.000 claims abstract description 16
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 15
- DKNDOKIVCXTFHJ-HNNXBMFYSA-N 3,5-dichloro-n-[[1-[[(4s)-2,2-dimethyloxan-4-yl]methyl]-4-fluoropiperidin-4-yl]methyl]benzamide Chemical compound C1COC(C)(C)C[C@H]1CN1CCC(F)(CNC(=O)C=2C=C(Cl)C=C(Cl)C=2)CC1 DKNDOKIVCXTFHJ-HNNXBMFYSA-N 0.000 claims abstract description 13
- 230000027311 M phase Effects 0.000 claims abstract description 11
- 241000124008 Mammalia Species 0.000 claims abstract description 11
- 230000010337 G2 phase Effects 0.000 claims abstract description 5
- 230000002250 progressing effect Effects 0.000 claims abstract description 5
- 230000010190 G1 phase Effects 0.000 claims abstract 4
- 101710112752 Cytotoxin Proteins 0.000 claims description 17
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 17
- 239000002619 cytotoxin Substances 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 16
- 230000012820 cell cycle checkpoint Effects 0.000 claims description 14
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 claims description 13
- 229960004438 mibefradil Drugs 0.000 claims description 12
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 11
- 229960004964 temozolomide Drugs 0.000 claims description 11
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 9
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 7
- -1 6-mecaptopurine Chemical compound 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 229960004768 irinotecan Drugs 0.000 claims description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 claims description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 230000002927 anti-mitotic effect Effects 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229960003901 dacarbazine Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229950003102 efonidipine Drugs 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- 229960004355 vindesine Drugs 0.000 claims description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 2
- 229960002066 vinorelbine Drugs 0.000 claims description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 59
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 13
- 102000003691 T-Type Calcium Channels Human genes 0.000 description 9
- 108090000030 T-Type Calcium Channels Proteins 0.000 description 9
- 230000011278 mitosis Effects 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000000480 calcium channel blocker Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000016507 interphase Effects 0.000 description 6
- 229940127291 Calcium channel antagonist Drugs 0.000 description 5
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 5
- 230000009460 calcium influx Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229950006344 nocodazole Drugs 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 102000003922 Calcium Channels Human genes 0.000 description 3
- 108090000312 Calcium Channels Proteins 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 230000003185 calcium uptake Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000013043 chemical agent Substances 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000004941 influx Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000018486 cell cycle phase Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101000932804 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1H Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100025482 Voltage-dependent T-type calcium channel subunit alpha-1H Human genes 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000013476 bayesian approach Methods 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000029115 microtubule polymerization Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000006516 vital cellular process Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18465809P | 2009-06-05 | 2009-06-05 | |
| US61/184,658 | 2009-06-05 | ||
| PCT/US2010/037437 WO2010141842A2 (en) | 2009-06-05 | 2010-06-04 | Interlaced method for treating cancer or a precancerous condition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2764499A1 true CA2764499A1 (en) | 2010-12-09 |
Family
ID=43298556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2764499A Abandoned CA2764499A1 (en) | 2009-06-05 | 2010-06-04 | Interlaced method for treating cancer or a precancerous condition |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20120088807A1 (enExample) |
| EP (1) | EP2437749B8 (enExample) |
| JP (2) | JP5806210B2 (enExample) |
| KR (2) | KR20120030112A (enExample) |
| CN (2) | CN106177963A (enExample) |
| AU (1) | AU2010256442B2 (enExample) |
| CA (1) | CA2764499A1 (enExample) |
| DK (1) | DK2437749T3 (enExample) |
| ES (1) | ES2661216T3 (enExample) |
| IL (2) | IL216443A (enExample) |
| MX (1) | MX344725B (enExample) |
| PL (1) | PL2437749T3 (enExample) |
| SG (3) | SG176678A1 (enExample) |
| WO (1) | WO2010141842A2 (enExample) |
| ZA (1) | ZA201108909B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2542155B1 (en) | 2010-03-01 | 2015-11-04 | TAU Therapeutics LLC | Method for imaging a disease |
| SG10201601917XA (en) * | 2011-09-12 | 2016-04-28 | Tau Therapeutics Llc | Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
| US11058624B2 (en) | 2014-02-06 | 2021-07-13 | The Procter And Gamble Company | Hair care composition comprising cationic polymers and anionic particulates |
| US11642353B2 (en) | 2014-02-06 | 2023-05-09 | The Procter & Gamble Company | Hair care composition comprising antidandruff agent and polyquaternium-6 |
| CA3002831C (en) | 2015-10-22 | 2024-04-16 | Cavion, Inc. | Methods for treating angelman syndrome and related disorders |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CA3053781A1 (en) | 2017-02-15 | 2018-08-23 | Cavion, Inc. | Benzopyran and naphalene derivatives and their uses as calium channel inhibitors |
| CN110770221B (zh) | 2017-04-26 | 2023-09-08 | 卡维昂公司 | 用于改善记忆和认知以及用于治疗记忆和认知障碍的方法 |
| CA3115235A1 (en) | 2018-10-03 | 2020-04-09 | Cavion, Inc. | Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
| US11964038B2 (en) | 2018-10-04 | 2024-04-23 | The Procter & Gamble Company | Personal care composition comprising water insoluble solid organic compound |
| BR112021013766A2 (pt) | 2019-03-01 | 2021-09-21 | Flamel Ireland Limited | Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251886B1 (en) * | 1998-12-07 | 2001-06-26 | Schering Corporation | Methods of using temozolomide in the treatment of cancers |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US20060003020A1 (en) * | 2004-03-11 | 2006-01-05 | The Regents Of The University Of Michigan | Anti-metastatic ability of mibefradil and gadolinium |
| TW200538149A (en) * | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| US20060000320A1 (en) * | 2004-06-30 | 2006-01-05 | Hutton William M | Ratchet wrench tool assembly for underground work and process of using |
| ATE552233T1 (de) * | 2004-08-20 | 2012-04-15 | Univ Virginia Patent Found | T-typ-calciumkanalinhibitoren |
| WO2006023881A2 (en) * | 2004-08-20 | 2006-03-02 | University Of Virginia Patent Foundation | T type calcium channel blockers and the treatment of diseases |
| CN100546579C (zh) * | 2006-12-30 | 2009-10-07 | 南京工业大学 | 替莫唑胺聚乳酸纳米微球与制剂及其制备方法 |
| WO2008141189A1 (en) * | 2007-05-09 | 2008-11-20 | Elixir Pharmaceuticals, Inc. | Ghrelin modulating compounds and combinations thereof |
-
2010
- 2010-06-04 AU AU2010256442A patent/AU2010256442B2/en not_active Ceased
- 2010-06-04 EP EP10784166.0A patent/EP2437749B8/en not_active Not-in-force
- 2010-06-04 US US13/375,846 patent/US20120088807A1/en not_active Abandoned
- 2010-06-04 SG SG2011089885A patent/SG176678A1/en unknown
- 2010-06-04 CA CA2764499A patent/CA2764499A1/en not_active Abandoned
- 2010-06-04 KR KR1020117031182A patent/KR20120030112A/ko not_active Ceased
- 2010-06-04 SG SG10201402863PA patent/SG10201402863PA/en unknown
- 2010-06-04 KR KR1020177022797A patent/KR101905050B1/ko not_active Expired - Fee Related
- 2010-06-04 MX MX2011012940A patent/MX344725B/es active IP Right Grant
- 2010-06-04 CN CN201610829079.8A patent/CN106177963A/zh active Pending
- 2010-06-04 WO PCT/US2010/037437 patent/WO2010141842A2/en not_active Ceased
- 2010-06-04 DK DK10784166.0T patent/DK2437749T3/da active
- 2010-06-04 SG SG10201810806UA patent/SG10201810806UA/en unknown
- 2010-06-04 JP JP2012514182A patent/JP5806210B2/ja not_active Expired - Fee Related
- 2010-06-04 PL PL10784166T patent/PL2437749T3/pl unknown
- 2010-06-04 CN CN2010800247574A patent/CN102458416A/zh active Pending
- 2010-06-04 ES ES10784166.0T patent/ES2661216T3/es active Active
-
2011
- 2011-11-17 IL IL216443A patent/IL216443A/en active IP Right Grant
- 2011-12-05 ZA ZA2011/08909A patent/ZA201108909B/en unknown
-
2015
- 2015-09-03 JP JP2015173818A patent/JP6159958B2/ja not_active Expired - Fee Related
-
2016
- 2016-10-25 IL IL248482A patent/IL248482B/en not_active IP Right Cessation
-
2018
- 2018-01-12 US US15/870,355 patent/US20180228822A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201402863PA (en) | 2014-10-30 |
| IL216443A0 (en) | 2012-02-29 |
| US20120088807A1 (en) | 2012-04-12 |
| SG10201810806UA (en) | 2019-01-30 |
| EP2437749A2 (en) | 2012-04-11 |
| JP6159958B2 (ja) | 2017-07-12 |
| CN106177963A (zh) | 2016-12-07 |
| KR101905050B1 (ko) | 2018-10-08 |
| AU2010256442B2 (en) | 2016-07-21 |
| JP2012528890A (ja) | 2012-11-15 |
| US20180228822A1 (en) | 2018-08-16 |
| KR20120030112A (ko) | 2012-03-27 |
| ZA201108909B (en) | 2013-02-27 |
| KR20170097237A (ko) | 2017-08-25 |
| JP2016028058A (ja) | 2016-02-25 |
| EP2437749B1 (en) | 2017-12-20 |
| ES2661216T3 (es) | 2018-03-28 |
| IL248482A0 (en) | 2016-12-29 |
| EP2437749B8 (en) | 2018-02-21 |
| EP2437749A4 (en) | 2013-04-17 |
| IL248482B (en) | 2020-08-31 |
| AU2010256442A1 (en) | 2012-01-19 |
| PL2437749T3 (pl) | 2018-04-30 |
| WO2010141842A2 (en) | 2010-12-09 |
| SG176678A1 (en) | 2012-01-30 |
| MX344725B (es) | 2017-01-05 |
| CN102458416A (zh) | 2012-05-16 |
| JP5806210B2 (ja) | 2015-11-10 |
| DK2437749T3 (da) | 2018-01-29 |
| MX2011012940A (es) | 2012-04-20 |
| IL216443A (en) | 2016-11-30 |
| WO2010141842A3 (en) | 2011-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2437749B1 (en) | Interlaced method for treating cancer or a precancerous condition | |
| Guise | Antitumor effects of bisphosphonates: promising preclinical evidence | |
| RU2767664C2 (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| EP1781276B1 (en) | Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain | |
| RU2764175C1 (ru) | Бифункциональные композиции для лечения рака | |
| JP2018087228A (ja) | がんのためのグルフォスファミド組み合わせ療法 | |
| SK13912002A3 (sk) | Farmaceutické prostriedky na vyvolanie účinku, ktorý poškodzuje cievy | |
| US20240082177A1 (en) | Use of cysteamine and derivatives thereof to suppress tumor metastases | |
| WO2016166761A1 (en) | Combination therapies and uses thereof in the treatment of cancer | |
| HK1168764B (en) | Interlaced method for treating cancer or a precancerous condition | |
| HK1168764A (en) | Interlaced method for treating cancer or a precancerous condition | |
| JP2015505313A (ja) | 癌を治療するための併用療法 | |
| JP2014221752A (ja) | ガン幹細胞に対する分化促進薬及び脳腫瘍治療薬 | |
| Ozkan et al. | Post-operative sequential chemo-radiotherapy in high-grade cerebral gliomas with fotemustine | |
| UA125142C2 (uk) | Комбінація інгібітору mcl-1 і таксанової сполуки, її застосування та фармацевтична композиція | |
| CN119235866B (zh) | Sn38和az20在制备治疗脑干胶质瘤药物中的用途 | |
| TW201513871A (zh) | 用於癌症治療之抗群集素（ｃｌｕｓｔｅｒｉｎ）單一療法 | |
| CN111407748A (zh) | 酪醇在制备治疗脑胶质瘤的药物中的应用 | |
| Arita et al. | 219 Prediction of carboplatin clearance on Japanese lung cancer patients | |
| Sørensen et al. | 218 Phase II study of bi-weekly paclitaxel (P) and cisplatin (C) for non-resectable non small-cell lung cancer (NSCLC) | |
| Zaniboni et al. | 220 Taxol, ifospamide and carboplatin for NSCLC: A phase II study | |
| WO2018069924A1 (en) | Non-cytotoxic combination therapies and uses thereof in the treatment of cancer | |
| Ruotsalainen et al. | 221 IFN-α and retinoic acid maintenance therapy for SCLC | |
| MX2013004423A (es) | Uso de cisteamina y derivados de la misma para suprimir metastasis de tumor. | |
| HK1202419B (en) | Combination therapy with a mitotic inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150603 |
|
| FZDE | Discontinued |
Effective date: 20220617 |
|
| FZDE | Discontinued |
Effective date: 20220617 |